// App-Quantinova.ai

3414 : Comparison of Reduced-Intensity Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Patients 50 Years or Older

Researchers

Presenter

  • Koji Kawamura

Principal Investigators

  • Shinichi Kako

  • Shuichi Mizuta

  • Tatsuo Ichinohe

  • Yoshiko Atsuta

  • Yoshinobu Kanda

  • Ken Ishiyama

  • Jun Aoki

  • Shingo Yano

  • Takahiro Fukuda

  • Naoyuki Uchida

  • Yukiyasu Ozawa

  • Tetsuya Eto

  • Koji Iwato

Medical Centers

  • Clinical Oncology and Hematology, The Jikei University School of Medicine, Tokyo, Japan

  • Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

  • Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan

  • Department of Surgery, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan

  • Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital,

  • Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

  • Department of Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan

  • Japanese Data Center for Hematopoietic Cell Transplantation,

  • Department of Medicine, Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital, Tokyo, Japan

  • Division of Hematology, Jichi Medical University, Tochigi, Japan

  • Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan

  • Departments of Surgery, Fujita Health University School of Medicine, Toyoake, Japan

  • Department of hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan

  • Department of Pediatrics, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Anemia

  • Acute Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • fludarabine tablet

  • Melphalan

  • Busulfan

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved